Hims & Hers: Ride the Relief, Not the Euphoria
HIMS gapped higher after settling with Novo Nordisk and striking a distribution deal for Wegovy/Ozempic; the move removes a headline risk and creates a tactical mid-term buying opportunity. Valuation is reasonable relative to growth expectations but volatility, execution risk on international expansion, and GLP-1 market dynamics argue for a discipl…